• Alexander D. Makatsariya
  • Gian C. Di Renzo
  • Giuseppe Rizzo
  • Viktoria O. Bitsadze
  • Jamilya Kh Khizroeva
  • Dmitry V. Blinov
  • Elena I. Vovk
  • Igor E. Govorov
  • Dmitry L. Guryev
  • Galina B. Dikke
  • Marina S. Zainulina
  • Natalya S. Zakharova
  • Vladislav V. Kovalev
  • Vladimir A. Kramarskiy
  • Alexander B. Loginov
  • Larisa I. Maltseva
  • Vyacheslav B. Nemirovskiy
  • Dmitry A. Ponomarev
  • Elena B. Rudakova
  • Natalia V. Samburova
  • Olga F. Serova
  • Faina K. Tetelyutina
  • Maria V. Tretyakova
  • Jumber Yu Ungiadze
  • Valentina I. Tsibizova

An issue of habitual miscarriage poses a high social importance especially during COVID-19 pandemic. Meanwhile, healthcare workers faced a mass media campaign against using micronized progesterone upon habitual miscarriage, which, as viewed by us, displays signs of prejudiced data manipulation and may disorient practitioners. In this Letter we provide objective information on accumulated data regarding gestagenes efficacy and safety. We invoke healthcare professionals to make decisions deserving independent primary source trust presented by original scientific papers published in peer-reviewed journals, clinical recommendations proposed by professional medical communities as well as treatment standards and protocols.

Translated title of the contributionRegarding the evidence-based use of micronized progesterone
Original languageRussian
Pages (from-to)374-383
Number of pages10
JournalObstetrics, Gynecology and Reproduction
Volume14
Issue number3
DOIs
StatePublished - 2020

    Scopus subject areas

  • Reproductive Medicine
  • Embryology
  • Obstetrics and Gynecology

ID: 87783955